$AGN.C just announced positive topline data showing that it has met the co-primary endpoint in its Phase 2 proof of concept study evaluating Ifenprodil for the potential treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. There’s a lot of data to unpack here, so I’ll list some of the key data points below that show the efficacy of the Ifenprodil in the study.
- For Ifenprodil in IPF patients, lung function in this trial was measured by FVC (a best-efforts measurement), which was taken for each patient at baseline, and then again at 12 weeks. Patients whose FVC declined were classified as non-responders, while those whose FVC improved or remained stable were classified as responders.
- Of the 20 patients, 65% were responders, which is statistically significant over a placebo trial of just 40% showing improvement/stability (further supporting previous placebo trial data)
- For the chronic cough part, 30% of subjects achieved the endpoint of a 50% reduction in the average number of coughs per hour over 24 hours from baseline to week 12. However, it was not statistically significant above the placebo of 25%.
- Even if it wasn't significant, there were definitely some interesting results showing potential with Ifenprodil.
Check out the full article here: https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-hits-co-primary-120000001.html
Overall, these results show that there's potential and a future for Ifenprodil. I'll be looking towards their further studies as they progress through Phase 2 trials here. It's definitely speculative (as with all pre-approval pharma companies), but with these new results and only a $5.8M market cap, there's a lot of upside potential for the company, especially with the new $25 price target.
I'd highly recommend watching this interview that goes more in-depth into the trial: https://themarketherald.ca/algernon-pharmaceuticals-hits-co-primary-endpoint-in-its-phase-2-study-of-ifenprodil-for-idiopathic-pulmonary-fibrosis-and-chronic-cough-2022-07-18/